This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Beigene, Ltd.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Profile of Inventor Qinzhou Qi: Innovating Immunotherapy for Hepatocellular Carcinoma
Introduction: Qinzhou Qi is a prominent inventor based in Beijing, China, known for his groundbreaking work in the field of immunotherapy. With a focus on novel approaches to combat hepatocellular carcinoma, his research has made significant strides in cancer treatment.
Latest Patents: Qi holds a patent for an innovative method aimed at preventing, delaying the progression, or treating hepatocellular carcinoma. The patent outlines a method that involves administering a therapeutically effective amount of an anti-PD-1 antibody, which specifically binds to human PD-1. This development showcases his commitment to advancing medical treatments that can potentially improve patient outcomes.
Career Highlights: Qinzhou Qi has had a notable career in the biopharmaceutical industry, particularly with Beigene, Ltd. His work emphasizes a strong dedication to innovative therapies that address critical health challenges. Through his contributions, Qi has positioned himself at the forefront of cancer research and treatment development.
Collaborations: Throughout his career, Qi has worked alongside esteemed colleagues, including Lai Wang and Kang Li. These collaborations have enriched his research endeavors and expanded the impact of his innovations in the medical field.
Conclusion: Inventor Qinzhou Qi continues to make significant contributions to the field of immunotherapy, particularly in the treatment of hepatocellular carcinoma. His achievements and collaborations reflect a commitment to innovation that holds promise for future advancements in cancer care. Through his patented work, Qi is paving the way for transformative therapies that may change the landscape of cancer treatment.